The present invention provides mTOR inhibitors of the formula
wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods of making the compounds and intermediates thereof; and methods of using the compounds.
The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I,
wherein the variables Q
1
, R, and X are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.